Project Grant R00HL165024
Award Date 3/10/26
Completion Date 2/28/29
Dollars Obligated $249K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $134,250 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 1, 2026 through January 31, 2028. The award funds research services focused on conducting integrative single-cell analysis of aging-associated changes in human hematopoietic stem cell (HSC) heterogeneity. The project applies advanced computational algorithms,...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received an $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025, and ultimate completion date of June 30, 2030. This research initiative investigates endothelial inflammation, Src kinase dysregulation, and fibrosis mechanisms in early pulmonary arterial hypertension (PAH), with particular...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $1.24 million project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) awarded March 1, 2026, with a completion date of February 28, 2033. The award funds research into non-coding ribonucleic acids (ncRNAs), including microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), as therapeutic targets for chronic limb-threatening ischemia...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $787,453 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025, and ultimate completion date of June 30, 2029. The grant funds research and development of a novel lipid-lowering and anti-inflammatory small interfering ribonucleic acid (siRNA) therapy for atherosclerotic cardiovascular disease...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $855,585 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 20, 2025, with completion scheduled for July 31, 2028. This award funds preparatory research to adapt and test an antihypertensive self-titration intervention for implementation in the U.S. primary care context. The project addresses the significant public...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received a $763,858 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through June 30, 2030. Under the direction of Principal Investigator Dr. Jennifer Manne-Goehler and an interdisciplinary team of experts from Massachusetts General Hospital, Case Western University, and University of Michigan, this award funds the...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $784,362 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, with completion scheduled for May 31, 2030. The award supports a comprehensive research initiative titled "Beyond BMI: Role of Body Composition, Coronary Microvascular Dysfunction and HFPEF in Characterizing Cardiometabolic...
- Federal Project Grant Award Summary Boston Children's Hospital received a $117,525 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective July 7, 2025, with completion targeted for June 30, 2028. This award supports research investigating cellular adaptation mechanisms in response to one-carbon (1C) metabolism disruption, with a specific focus on understanding how erythroid cells respond to folate...
- Federal Grant Award Summary Boston Medical Center Corporation received a $1.42 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2025, through February 28, 2030. The award supports research to elucidate the endothelial mechanisms that regulate hematopoietic stem cell (HSC) extravasation—the process by which circulating stem cells cross blood vessel walls and enter their bone marrow...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Brigham and Women's Hospital a Project Grant of $133,221 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837), with a completion date of August 31, 2030. This research initiative focuses on linking mechanisms to outcomes in airway inflammation and remodeling, with primary emphasis on chronic rhinosinusitis (CRS) and asthma—two prevalent chronic inflammatory diseases that...